Core Insights - Syra Health reported a strong financial performance for FY2025, with a 157% growth in population health revenue and a 76% reduction in net loss, targeting profitability by the end of 2026 [1][2] Financial Performance - Population health revenue increased to $5.3 million in FY2025 from $2.1 million in FY2024, marking a 157% year-over-year growth [1] - Total revenue for FY2025 was $7.2 million, a 9% decrease from $8.0 million in FY2024, primarily due to reduced federal government funding [1][2] - Net loss improved to ($896K) in FY2025 from ($3.8M) in FY2024, reflecting a 76% reduction [1][2] - Earnings per share (EPS) improved to ($0.08) in FY2025 from ($0.50) in FY2024 [1] - Gross margin increased to 34.4% in FY2025 from 20.7% in FY2024, a 14 percentage point rise attributed to better operational efficiency [1] Operational Highlights - Operating expenses decreased by 37% to $3.4 million in FY2025 compared to $5.4 million in FY2024 [1] - The company launched a wellness pilot program in collaboration with a public health department in North Carolina [1] - Syra Health submitted Syrenity for FDA approval under the TEMPO pilot program, aiming to participate in CMS's ACCESS Model starting July 2026 [1] Future Outlook - The company anticipates achieving profitability by year-end 2026, driven by strong demand for its population health solutions and disciplined cost management [1] - Management expressed confidence in the company's path to profitability, highlighting the combination of revenue growth and cost restructuring [1]
Syra Health Posts Strong FY2025 Results with 157% Population Health Growth and 76% Net Loss Reduction: Targets Profitability by Year-End 2026